Recent studies in SMA mice suggest that myostatin inhibition, together with an SMN‐restoring small molecule therapy, could be potentially beneficial.26, 27 A number of questions however remain unanswered: what is an optimal timing for considering myostatin inhibition in SMA? The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.